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Abstract
Background: Gulf War Illness (GWI) is a complex multi-symptom disorder that affects up to one in three veterans
of this 1991 conflict and for which no effective treatment has been found. Discovering novel treatment strategies
for such a complex chronic illness is extremely expensive, carries a high probability of failure and a lengthy cycle
time. Repurposing Food and Drug Administration approved drugs offers a cost-effective solution with a significantly
abbreviated timeline.
Methods: Here, we explore drug re-purposing opportunities in GWI by combining systems biology and bioinformatics
techniques with pharmacogenomic information to find overlapping elements in gene expression linking GWI to
successfully treated diseases. Gene modules were defined based on cellular function and their activation estimated
from the differential expression of each module’s constituent genes. These gene modules were then cross-referenced
with drug atlas and pharmacogenomic databases to identify agents currently used successfully for treatment in other
diseases. To explore the clinical use of these drugs in illnesses similar to GWI we compared gene expression patterns in
modules that were significantly expressed in GWI with expression patterns in those same modules in other illnesses.
Results: We found 19 functional modules with significantly altered gene expression patterns in GWI. Within these
modules, 45 genes were documented drug targets. Illnesses with highly correlated gene expression patterns
overlapping considerably with GWI were found in 18 of the disease conditions studied. Brain, muscular and
autoimmune disorders composed the bulk of these.
Conclusion: Of the associated drugs, immunosuppressants currently used in treating rheumatoid arthritis, and
hormone based therapies were identified as the best available candidates for treating GWI symptoms.
Keywords: Gulf war illness, Systems biology, Bioinformatics, Drug repurposing, Pharmacogenomics,
Complex chronic illness
Background
Novel drug discovery is a costly, high-risk and extremely
time-consuming enterprise. Costing in the range of millions
to billions of dollars [1–4], the process can take up to
15 years to complete with one of every two novel drug can-
didates failing in the later stages [5]. As such, the repurpos-
ing of Food and Drug Administration (FDA) approved
drugs offers a fast cost effective solution for discovering
novel treatments. This is all the more true for conditions
with no known treatments.
Gulf War Illness (GWI) is but one example of a com-
plex chronic illness with no known cure and which re-
quires long-term treatment and monitoring. This both
prolongs patient suffering and increases the financial
burden of the illness, for the individual, the family and
society. GWI is a multi-symptom disorder exhibiting a
complex constellation of symptoms that include fatigue,
musculoskeletal pain, and cognitive dysfunction [6].
Since returning from the first Gulf War over 20 years
ago investments of nearly $1 billion have been made to
Gulf War Veterans health [6], however there is still no
effective treatment available for the nearly 250,000
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veterans with GWI. Though the cause and illness mech-
anisms of GWI are largely unknown, a leading hypoth-
esis points to the involvement of neuroinflammatory
cascade possibly triggered by exposure to battlefield
toxins and exacerbated by stress [7–9]. Thus, this illness
has far-reaching consequences and the development of
effective treatments promises to benefit not only this pa-
tient population but a host of others as well.
In an attempt to identify candidate treatment avenues
for GWI involving currently approved pharmacological
agents we used a combination of systems biology and bio-
informatics techniques combined with pharmacogenomic
information to compare gene expression patterns in GWI
to known drug targets and expression patterns found in a
set of human diseases. We identified a specific set of func-
tional gene modules with altered expression in GWI
pointing to the cellular processes affected in this disorder.
Significant correlations between gene expression profiles
in these gene modules were found between GWI and
other disease conditions. Cross-referencing of disease and
drug information in pharmacogenomic databases with
druggable genes in these functional modules ultimately re-
vealed novel drug repurposing avenues for the treatment
of GWI.
Methods
GWI cohort
As part of a larger ongoing study a subset of GWI male
subjects (n = 17) and healthy but sedentary Gulf War era
veterans (n = 22) were recruited from the Miami Veterans
Administration Medical Centers, clinics and the local vet-
eran community between April 2006 and May 2008. All
subjects were comparable in age, body mass index (BMI),
and ethnicity. Subjects were male and ranged in age be-
tween 30 and 55. Inclusion criteria was derived from
Fukuda et al. [10], and consisted in identifying veterans de-
ployed to the theater of operations between August 8, 1990
and July 31, 1991, with one or more symptoms present
after 6 months from at least 2 of the following: fatigue;
mood and cognitive complaints; and musculoskeletal com-
plaints. Subjects were in good health prior to 1990, and had
no current exclusionary diagnoses [11]. Medications that
could have impacted immune function were excluded. Use
of the Fukuda definition in GWI is supported by Collins et
al. [12]. Additional details may be found in Broderick et al.
[13].
All subjects signed an informed consent approved by
the Institutional Review Board of the University of Miami.
Ethics review and approval for data analysis was also ob-
tained by the IRB of the University of Alberta.
Gene expression
Blood was drawn at rest at comparable times of day from
each subject during the April 2006 to May 2008 period. At
each blood draw three 8-mL tubes of blood were collected
in CPT vacutainers (B-D- Biosciences, San Jose, CA). The
peripheral blood mononuclear cells (PBMC) were isolated
and stored in liquid nitrogen under conditions designed to
maintain viability. Specifically, whole blood was added to
Ficoll-Paque, centrifuged at 1000 g for 25 min. PBMC’s
were isolated from the PBMC ring atop the Ficoll layer into
a separate tube, centrifuged at 300 g for 10 min, then re-
suspended in PBS. Cells were then counted using a Beck-
man Coulter viCell, and cryopreserved in freezing media
(temperature lowered 1 oC per minute until -80 oC).
Total RNA was extracted using TRI Reagent (Molecular
Research Center, Cincinnati, OH) following the manufac-
turer’s protocol. The quality and quantity of RNA was
assessed using the Agilent Bioanalyzer 2100 RNA 6000
Nano Kit (Agilent Technologies, CA). From each sample,
300 ng of total RNA was converted into cDNA by reverse
transcription using a T7-oligo(dT) primer and the Affyme-
trix 3′ IVT Express Kit (Affymetrix, Santa Clara, CA) ac-
cording to standard manufacturer protocol. The generated
cDNA was purified using the GeneChip Sample Cleaning
Module (Affymetrix) and labeled cRNA was generated by
in vitro transcription using the biotinylated nucleotide
mix. This was then purified with the Cleaning Module
and quantified using the Nanodrop ND-1000 spectropho-
tometer (NanoDrop Technologies, Inc., Wilmington, DE
USA). In each preparation 11 μg cRNA was fragmented in
Fragmentation Buffer (Affymetrix) in a final reaction vol-
ume of 25 μl.
Hybridization, washing, staining and scanning were done
using Affymetrix GeneChip instruments (Hybridization
Oven 640, Fluidics Station 450Dx, Scanner GCS3000Dx)
and Affymetrix Human U133 2.0 arrays (Affymetrix) as per
manufacturer’s standards. Microarray image files (.cel data)
were generated using the Affymetrix GCOS software tool
with default microarray analysis parameters to provide over-
all within chip normalization of the image intensity distribu-
tion. The quality parameters that were monitored besides
cRNA total yield and cRNA A260/A280 ratio included: (i)
background noise (Q value), (ii) percentage of present called
probe sets, (iii) scaling factor, (iv) information about exogen-
ous Bacillus subtilis control transcripts from the Affymetrix
Poly-A control kit (lys, phe, thr, and dap), and (v) the ratio
of intensities of 3′ probes to 5′ probes for a housekeeping
gene (GAPDH).
To generate a broad comparison group the Gene Expres-
sion Omnibus (GEO) DataSets [14, 15] and data from
Suthram et al. [16] were used to obtain a set of gene expres-
sion profiles describing a number of human disease condi-
tions. We restricted our selection to include only those sets
in which both disease and a corresponding healthy control
group were measured in the same cell type or tissue in the
same experimental conditions. Sets that included different
exposure times, exposure concentrations or multiple cell/
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tissue types were each treated as a separate disease condi-
tion. For consistency, and to avoid complications arising
due to cross platform comparisons, datasets were restricted
to the Affymetrix Gene Chip Human Genome U133A,
U133 Plus 2.0, U133A 2.0 and U95 Version 2 arrays, to
align with our GWI gene expression data. All diseases af-
fecting male subjects in the GEO database meeting these
criteria were included in this study. Overall, this resulted in
101 human disease gene expression datasets (Additional
file 1: Table S1). The disease profiles selected provide a
comprehensive set of diseases and include various cancers,
neurodegenerative diseases, autoimmune illnesses, chemical
exposures, viral infections, neurological and neuromuscular
disorders.
Data transformation and normalization
Gene expression data was Log2 transformed then normal-
ized using a Z-score transformation for each microarray
sample to allow for the direct comparison of values across
various samples and diseases.
Gene functional modules
Here we use 4,620 functional modules defined by Suthram
et al. [16] from the human protein-protein interaction
network. Individual genes i in module j were compared
between GWI subjects and healthy controls using an un-
paired t-test to generate a T-Score, Gij. Differential module
activity (MAj) was determined using the average of the ab-
solute T-Score values for all Nj genes in a given module, j,
such that:
MAj ¼
XNj
i¼1 Gij j
Nj
ð1Þ
This is a modification of the module activity described
in [16] were the signed T-score was used. When averaging
over signed T-scores equal but opposite scores will tend
to cancel, resulting in no module activity, when in fact
there are genes significantly over or under expressed. Here
the absolute value was used in the differential module ac-
tivity to capture both up and down-expressed genes. A
threshold of MA= 1.5, corresponding to a p-value of ~0.1,
was chosen as a liberal cutoff value to identify differen-
tially expressed gene modules. Only modules with MA
values above threshold were taken to be differentially
expressed in GWI and considered for further analysis, all
others were discarded.
Individual gene expression analysis
The 202 genes in the 19 modules with MA values above
threshold were individually compared between GWI and
controls. Individual genes i were compared between GWI
subjects and healthy controls using an unpaired t-test. To
account for multiple comparisons false discovery rates
(FDR) were then calculated for each comparison from these
resulting p-values using the procedure introduced by Storey
[17]. Genes with FDR of less than or equal to 0.05 were
taken to be significantly different in GWI compared to con-
trol. Fold change was calculated by calculating the ratio of
average gene expression between GWI and health controls
for non-Log2 transformed data. Positive values were taken
to indicate the fold-increase while ratios that were less than
1 were inverted and given a negative value to denote the
fold-decrease. An absolute fold change of 1.5 was taken as
a cutoff [18].
Mining the pharmacogenomic knowledge base
(PharmGKB) database
Genes from modules affected in GWI were screened
against the PharmGKB database (8.1.2015) [19] to find
gene-drug and gene-disease relationships supported with
pharmacogenomics research reported in the literature.
Pathway-based functional annotation of gene modules
Functional annotation of gene modules with gene-drug
relations was performed using the ConsensusPathDB
[20–22] to provide biological pathway information for
each gene set. Over-representation analysis [20] incorp-
orating the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (73.0) [23], Netpath (1.1.2015) [24], the Small
Molecule Pathway Database (SMPDB) (8.1.2015) [25],
the Integrating Network Objects with Hierarchies
(INOH) (1.1.2015) [26], Biocarta (2009_05_12) [27],
Humancyc (18.5) [28], Signalink (8.1.2015) [29], Edin-
burgh human metabolic network (Ehmn) (1.1.2015)
[30], Reactome (51) [31], PharmGKB (8.1.2015) [19],
Wikipathways (9.1.2015) [32] and the Pathway Inter-
action Database (PID) (2014_02_14) [33] pathway sets
was used to interpret the function of druggable gene
modules. Here the significance of the observed overlap
between the gene module and the members of known
pathways, compared to random expectations, was calcu-
lated based on the hypergeometric distribution. A mini-
mum overlap of 2 genes between the gene module and
the pathway set at a p-value cutoff 0.01 was required.
Specifically, the p-value is calculated as the probability
of randomly finding k or more successes from the popu-
lation in N total draws. Thus, small p-values indicate a
greater overlap than expected by chance. Pathway sets
containing the majority of the druggable genes, the
highest number of module genes overall, and the lowest
p-value were taken as the functional annotation of the
module. Pathway annotation was performed only to
provide biological pathway information for each gene
module set. All subsequent analysis was performed on
these gene module sets constructed on the bases of hu-
man protein-protein interactions [16] and not on the
bases of known pathway membership.
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Gene module alignment across illnesses
To provide a quantitative measure of similarity in mod-
ule expression between GWI and another disease a par-
tial Spearman correlation was calculated between the T-
Score values of genes compared between select diseases
(Additional file 1: Table S1) and their controls within
each of the modules preferentially expressed in GWI
[16]. Partial correlation measures the degree of associ-
ation between two random variables, while removing the
effect of a set of controlling random variables. Partial
Spearman correlation was used to assess disease similar-
ity while explicitly factoring out dependencies between
different gene expression experiments [16]. The Partial
Spearman correlation coefficient between GWI (G) and
a disease condition (D), rGD,C, was conditioned on the T-
Score values between the control samples (C), corre-
sponding to each comparator disease, such that:
rGD;C ¼ rGD−rGCrDCﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−r2GC
 q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−r2DC
 q ð2Þ
with the generic Spearman correlation coefficient, rGD,
given as:
rGD ¼
XNj
i¼1 Gi−
Gð Þ Di−Dð ÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXNj
i¼1 Gi−
Gð Þ2
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXNj
i¼1 Di−
Dð Þ2
q ð3Þ
where Gi the ranked TScores between GWI and con-
trols, Di the ranked TScores between a given human dis-
ease condition and controls, and Ci the ranked TScores
between between GWI and human disease condition
control groups for the ith gene in module j containing Nj
genes. Note that the terms in the numerator of Equation
(2) are given by Equation (3) with substitutions for G, D,
and C appropriately as labeled. Here in Equation (3) the
barred terms ( G; D; C ) denote the averaging of all genes
in a given module. Correlations with p-values ≤ 0.01
were considered statistically significant. Additionally, as
we were looking for similarity between modules, inverse
correlations were not considered. Partial correlations
were calculated between GWI and the 101 disease con-
ditions (Additional file 1: Table S1) in the GWI affected
modules.
Significance of correlation
A random background distribution of disease correla-
tions across each module was created to determine if
module correlations between GWI and other diseases
were significantly different from random chance. Gene
to module assignments were first randomized, while pre-
serving the total number of modules, the number of
genes per module, and the number of modules to which
each gene belongs as in Suthram et al. [16]. Then
disease and control datasets for the disease conditions
were randomly shuffled before calculating partial corre-
lations with intact GWI datasets. This process was per-
formed 100 times for each module to generate the
random background distributions. The cumulative distri-
bution of the random background correlations per mod-
ule was used to calculate the p-value of the true
correlations in each module. FDR was calculated for
each correlation from these resulting p-values using the
procedure introduced by Storey [17]. Correlation values
with FDR of less than or equal to 0.05 were taken to be
significantly different from random background. All
others were removed.
Results
Affected genes and modules
A work flow illustrating the above methods is provided in
Additional file 2: Figure S1. In this work we found 19 of the
4,620 gene expression modules (~0.4 %) to be differentially
expressed in GWI compared to healthy controls. Many of
the modules (10 of 19) identified as being affected in GWI
shared common characteristics and were clustered together
across overlapping member genes (Fig. 1). Pathway-based
functional annotation of these gene modules provided bio-
logical pathway information for each gene set (Fig. 1) at a
significance of p < 0.1 and at a false discovery rate of q < 0.1.
Statistics for the pathway-based functional annotation can
be found in Additional file 3: Table S2. These 19 modules
were comprised of 202 individual genes. Of these 202 genes
54 were found to have a significant change of 1.5 fold or
more (See Additional file 4: Table S3).
Drug targetable affected genes
Cross-referencing the 202 genes in the 19 GWI affected
modules to drugs known to affect these genes using the
PharmGKB database (8.1.2015) [19] yielded 10 distinct cat-
egories of treatment, plus several uncategorized drugs
(Fig. 2). Of the compounds affecting the 45 targetable genes
6 were immunosuppressants (13 %), 5 were platinum com-
pounds (11 %), 4 were protein kinase inhibitors (9 %), 4
were pyrimidines (9 %), 3 were anti-neoplastics (7 %), 2
were hormones (4 %), 2 were monoclonal antibodies (4 %),
2 were anti-estrogens (4 %), 2 were taxanes (4 %), and 2
were anthracyclines (4 %), with the remainder being single
entries from unidentified drug classes. All identified drug
treatable genes were found in 8 of the 19 identified GWI
affected modules. Of the 45 targetable genes, only 7
showed a significant fold change in GWI: CCHCR1,
EGFR, ESR1, MAPK8, MAPK9, TRAF1 and XRCC1 (Fig. 2
and Additional file 4: Table S3).
Pathway representation in druggable gene modules
Of these 8 drug targetable GWI modules, 86.7 % of the
genes in module 2 belonged to the Tumor Necrosis Factor
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(TNF) alpha signaling pathway as annotated in the Net-
path database (1.1.2015) [24] (Additional file 3: Table S2).
This pathway includes both drug targetable genes, TNF
receptor-associated factor 1 (TRAF1) and the inhibitor of
kappa light polypeptide gene enhancer in B-cells, kinase
gamma (IKGBG). Overlapping with this module is module
14, which embodies much of the Immune System pathway
as annotated in the Reactome database (51) [31]. Overall,
73.3 % of the genes in module 14 are associated with
this pathway including the caspase 9, apoptosis-related
cysteine peptidase (CASP9) gene, and the CD40 molecule,
TNF receptor superfamily member 5 (CD40) gene.
Fig. 1 GWI Affected Modules. Network illustrating modules (colored spheres) identified as differentially expressed in GWI and their corresponding
gene (red spheres) associations. Edges denote gene membership within a given module consistent with previous methodologies [84]
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Modules 5, 8, 9, 17, and 18 overlap to form a cluster of
targetable genes. Module 5 was annotated as the PID
(2014_02_14) [33] pathway for the Validated Nuclear Es-
trogen Receptor Alpha Network. While only 21.4 % of the
genes in module 5 are included in this pathway, two of the
three drug targets identified are among these, namely the
breast cancer 1, early onset (BRCA1), and estrogen receptor
1 (ESR1) genes. The third druggable target, the X-ray repair
cross-complementing protein 1 (XRCC1) gene, however
was not included in the Validated Nuclear Estrogen Recep-
tor Alpha Network. The Netpath (1.1.2015) [24] Androgen
Receptor (AR) pathway was representative of the genes
present in module 8. A total of 62.4 % of the genes in this
module were found in the AR pathway, including 6 of the 7
drug targetable genes: BRCA1, cyclin D1 (CCND1), epider-
mal growth factor receptor (EGFR), nuclear receptor coacti-
vator 1 (NCOA1) catenin (cadherin-associated protein), beta
1, 88 kDa (CTNNB1), and signal transducer and activator of
transcription 3 (acute-phase response factor) (STAT3). Only
ESR1 was not affiliated with the AR pathway. The PID
(2014_02_14) [33] pathway for Signaling Mediated by p38-
alpha & p38 beta was assigned as the annotation for module
Fig. 2 GWI Affected Drug Targetable Genes. Network illustrating PharmGKB database (8.1.2015) [19] documented gene-drug (red-blue spheres) associations
for genes in GWI affected modules (overlapping colored circles) arranged according to drug families (colored bars). Gene module number scheme refers to
Fig. 1. Genes presented in boldface show a significant (p≤ 0.05) difference in GWI compared to controls with an absolute fold change greater than 1.5
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9. Both drug targetable genes, mitogen activated protein ki-
nases 11 and 14, are included among the 42.9 % of module
9 genes found in this pathway. Genes in both modules 17
and 18 were identified as part of the PID (2014_02_14) [33]
ATF-2 Transcription Factor Network. This pathway con-
tains 57.1 % and 66.7 % of the genes in module 17 and 18,
respectively, including all of the identified drug targets for
these modules, namely MAPK 1, 8, 9 and 14, and ESR1.
Finally, module 13 was enriched in genes from the
Reactome database (51) [31] Metabolism of Lipids & Li-
poproteins pathway. Only 21.4 % of the genes in the
module are included in this pathway, and the coiled-coil
alpha-helical rod protein 1 (CCHCR1) drug targetable
gene is not among them making this isolated pathway
uninformative for the selection of treatment repurposing
in GWI.
Similarity of GWI to known human diseases
We compared the 19 gene expression patterns in mod-
ules that were significantly expressed in GWI with ex-
pression patterns in those same modules in other
illnesses to find similarities between GWI and these ill-
nesses (Fig. 3). The average of all significant correlation
values across all GWI affected modules for a given dis-
ease gives a Global Alignment (GA) value describing the
similarity between GWI and the disease in question
(Additional file 1: Table S1). A GA value of 100 % indi-
cates perfect correlation across all 19 affected modules.
For example, Actinic Keratosis was found to be signifi-
cantly correlated with GWI in 6 of the 19 modules. The
sum of the 6 correlations values is 7.24 hence its GA
value is 7.24/19 = 38.1 %. All the correlations averaged in
the calculation of the GA are significant (p < 0.01; FDR
< 0.05) giving a measure of the degree to which each ill-
ness aligns with GWI. Eighteen disease conditions were
found to have GA values of 50 % or greater. These over-
whelmingly represented features shared by GWI with a
number of neurological and neurodegenerative illnesses
such as various forms of brain inflammation and degen-
eration including multiple sclerosis as well as muscle de-
generation, paraplegia and myopathy. Interestingly these
also included pathologic response to benzene exposure
(GA = 68 %) and chronic activation of the stress re-
sponse axis (GA = 65 %).
Refinement of drug targets through illness similarity
To focus on established clinical use of potential treat-
ments we further refined our initial list of 8 druggable
GWI gene modules through the cross-referencing of dis-
ease and drug information in the PharmGKB database
(8.1.2015) [19]. Illnesses showing gene expression pro-
files significantly correlated with GWI in the 8 druggable
gene modules were cross-referenced with drug agents
specifically used for their successful treatment. We
found one illness overlapping with specific druggable
components of GWI, namely rheumatoid arthritis (RA)
(GA = 16 %) (Fig. 3). The correlations between GWI and
RA occur along the Netpath (1.1.2015) [24] Tumor Ne-
crosis Factor (TNF) alpha pathway (R2 = 0.55), the PID
(2014_02_14) [33] annotated Validated Nuclear Estrogen
Receptor Alpha Network (R2 = 0.63), and ATF-2 Tran-
scription Factor Network (R2 = 0.54) pathways. The gene
encoding TRAF1 in the Netpath (1.1.2015) [24] Tumor
Necrosis Factor (TNF) alpha pathway is targeted with
the specific monoclonal antibodies against TNF-α inflixi-
mab and adalimumab, the chimeric protein etanercept,
and an overall class of TNF-α inhibitors in general
(Fig. 4). The drug-targetable ESR1 gene identified in RA
is annotated in PID (2014_02_14) [33] as part of both
the Validated Nuclear Estrogen Receptor Alpha Net-
work, and the ATF-2 Transcription Factor Network
pathways. Drugs identified in relation to these pathways
and RA are the immunosuppressant leflunomide, the
platinum compound cisplatin, general anti-neoplastic al-
kylating agents, and the estrogen modulating agents
medroxprogesterone, conjugated estrogens, tamoxifen,
fluvestrant, and exemestane (Fig. 4).
Discussion
GWI is a complex multi-symptom illness, which mani-
fests with cognitive dysfunction, fatigue, and musculo-
skeletal pain [6]. At this time it is unclear whether GWI
represents several syndromes, or one syndrome with
several subtypes. While stratification of the case defined
GWI subjects into subtypes based on shared clusters of
symptoms is an active area of research which may pro-
vide improved resolution on underlying gene functional
involvement, this issue will only be resolved when ob-
jective markers are firmly established. The analysis pre-
sented here is a step towards this goal.
Cognitive difficulties, such as memory problems, con-
stitute one of the most common unexplained impair-
ments reported in GWI [34]. Recent work examining
brain changes in GWI support an underlying neurobio-
logical underpinning to these problems. Results show
that participants with GWI perform significantly slower
and less accurately on working memory tasks than
matched healthy veterans, and that this decrease corre-
lates with lower levels of activity in prefrontal brain re-
gions [35]. Fatigue and pain, other commonly reported
symptoms associated with GWI have been linked to al-
terations in the brain’s white matter in GWI subjects
[36, 37]. Memory problems, as well as mood disorder,
have also been linked to mild inflammation and degener-
ations in the hippocampus in a mouse model of GWI
[38]. Our findings, indicate that over a third (38.9 %) of
the diseases aligning with greater than 50 % of the GWI
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affected modules are localized to the central nervous
system.
Musculoskeletal pain is another frequently reported
symptom of GWI [34]. A higher proportion of veterans
of the Persian Gulf War of 1991 reported symptoms of
muscle and joint pain than a military comparison group
[39]. This chronic pain has been linked to abnormal cen-
tral processing of sensory and painful stimuli in GWI
subjects in brain areas normally serving sensory percep-
tion, and threat and arousal, as well as in thalamocorti-
cal circuits and cerebellum [40]. GWI subjects suffering
from chronic musculoskeletal pain also experience
greater naturally occurring muscle pain during exercise
compared to healthy veterans and become more sensi-
tive to pain stimuli following acute exercise suggesting
that acute exercise augments the central nervous system
sensitivity to sensory information [41]. In this work we
find that more than 1 in 5 (22 %) of the diseases, which
overlap in gene expression with GWI, are muscular
disorders.
Evidence is mounting that there is also a significant im-
mune component to GWI. Ongoing Th1-type immune
activation, as measured by intracellular production of cy-
tokines in peripheral blood, appears to be symptomatic in
afflicted Gulf War Veterans when compared to healthy
counterparts [42]. More recently, this finding has been
confirmed while also suggesting that this may occur in the
more complex context of a mixed Th1:Th2 response [43].
In addition to this, our group previously reported altered
gene expression associated with NK cell function and
decreased NK cell cytotoxicity in GWI subjects [44].
Abnormal regulation of the immune system can result in
autoimmune diseases [45], and allergies [46]. Like GWI,
these illnesses are characterized by abnormal resting levels
(See figure on previous page.)
Fig. 3 Matrix of squared correlation values for GWI with all human diseases (Additional file 1: Table S1) in all affected modules (Fig. 1) with values
between 0 and 1 according to the color bar. Diseases are arranged in decreasing GA value and modules refer to those presented in Fig. 1 and
Additional file 3: Table S2. Dashed black line represent the GA 50 % mark. Modules are clustered hierarchically using a Euclidean distance metric
and average linkage to generate the hierarchical tree
Fig. 4 Summary of Results. Disease – Gene – Drug associations identified via the PharmGKB database (8.1.2015) [19]. Squared correlation values
of 0.542, 0.634, 0.551 for Rheumatoid Arthritis (RA) with GWI in the Netpath (1.1.2015) [24]: Tumor Necrosis Factor (TNF) alpha, PID (2014_02_14)
[33]: Validated Nuclear Estrogen Receptor Alpha Network, and PID (2014_02_14) [33]: ATF-2 Transcription Factor Network pathways, respectively
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of immune cells, cytokines and circulating hormones. Our
results indicate that close to 1 in 6 (17 %) of the overlap-
ping diseases are autoimmune disorders.
While gene expression in GWI was measured in PBMC,
gene expression in some of the other human illnesses was
obtained from brain tissue (e.g. hippocampus in FTLD,
substantia nigra in Parkinson’s). Although these measures
of pathway activation were expressed in different tissue,
substantial alignment between gene expression in blood
and brain biopsies has been shown in Parkinson’s, Alzhei-
mer’s and Huntington’s [48–50] supporting the relevance
of this profiling. When considered collectively, these find-
ings support an illness model whereby GWI might be de-
scribed primarily as a central nervous system disorder
manifesting with musculoskeletal problems that is poten-
tially fueled by a dysregulation of immunity. Central to
this would be an ongoing neuroinflammatory process.
A common issue in pathway analysis is that genes shared
between overlapping functional modules and pathways may
cause an inflated or biased p-value of statistical significance
for some annotations. In such situations highly influential
genes that are shared across multiple pathways may bias
the identification of some pathways unfairly. The current
analysis is not immune to this problem. As such it is pertin-
ent to examine the results in the context of the specific ill-
ness in question, and the individual genes highlighted by
the analysis. Pathway annotation of the drug treatable GWI
affected modules revealed two major pathway clusters. The
first is dominated by the Netpath (1.1.2015) [24] annotated
pathway for Tumor Necrosis Factor (TNF) alpha and the
Reactome (51) [31] Immune System pathway. Overall, this
cluster of pathways suggest that immune signaling, particu-
larly TNF-α signaling, are prime targets for repurposed
drug treatment in GWI. Projecting this onto known ill-
nesses with similar pathway involvement pointed to com-
monalities with RA. The relation between GWI and RA in
the Netpath (1.1.2015) [24]: Tumor Necrosis Factor (TNF)
alpha pathway identifies the gene encoding TRAF1 in con-
junction with several TNF-α inhibitors. Suppressed activity
of TNF receptor and apoptotic pathways [13], and higher
responsiveness of TNF-α [43, 45] have previously been
identified in GWI subjects by our group, consistent with
the current findings, suggesting an autoimmune compo-
nent to this illness. TNF-α blockers, such as infliximab, ada-
limumab and etanercept, are currently approved by the
FDA for the treatment of chronic inflammatory diseases
such as RA, Crohn’s disease and ankylosing spondylitis.
While, such treatments may affect immune function, indu-
cing autoantibodies leading to conditions such as drug-
induced lupus, there is low risk of infliximab, etanercept,
and adalimumab in association with drug-induced lupus
despite the higher incidence of autoantibodies with its use
[47]. As chronic inflammation is a suggested component of
GWI pathophysiology [51], these compounds may provide
a promising novel treatment avenue for GWI, however fur-
ther tests are required.
The second pathway cluster central to GWI that was
identified here is comprised of the Netpath (1.1.2015) [24]
Androgen Receptor (AR) pathway and PID (2014_02_14)
[33] Validated Nuclear Estrogen Receptor Alpha Network
as well as PID (2014_02_14) [33] pathways for the ATF-2
Transcription Factor Network, and Signaling Mediated by
p38-alpha and p38-beta. This large cluster is targetable by
the majority of identified drug classes including immuno-
suppressants, protein kinase inhibitors, hormone treatments,
estrogen receptor antagonists, monoclonal antibodies, tax-
anes, anti-neoplastics and platinum compounds. The p-38
MAPKs participate in signaling cascades that control
cellular responses to immune signals and stress, while
ATF-2 is normally activated in response to signals that
converge on the stress-activated p38 MAPKs. Both the
PID (2014_02_14) [33] pathway Validated Nuclear Estro-
gen Receptor Alpha Network pathway and Netpath
(1.1.2015) [24]: Androgen Receptor (AR) pathway high-
light sex steroid hormone pathways. As androgens are the
precursor of all estrogens, and both estrogen [52] and an-
drogen [53] receptor activity is mediated by p38 signaling,
this pathway cluster suggests that sex steroid signaling, as
mediated by p38, may also be prime targets for repur-
posed drug treatment in GWI.
Estrogen is also a potent, albeit complex, modulator of
inflammation [54]. The estrogen receptor 1 (ESR1) gene
is identified in relation to RA in both the PID database
(2014_02_14) [33] Validated Nuclear Estrogen Receptor
Alpha Network, and ATF-2 Transcription Factor Net-
work pathways. Leflunomide, an immunosuppressive
disease-modifying anti-rheumatic drug whose efficacy is
modulated by ESR1 gene polymorphisms [55], is the
only drug identified with a direct use in active moderate
to severe rheumatoid arthritis. The remainder of the
drug candidates identified in association with ESR1 and
RA are most commonly used in the treatment and pre-
vention of estrogen receptor positive cancers. Cisplatin,
a platinum-containing anti-cancer drug that binds DNA
resulting in apoptosis, also has immunosuppressive ef-
fects and has been shown to be effective in managing
RA in a recent single case study [56]. Alkylating agents,
drugs that modulate the immune system such as cyclo-
phosphamide, are sometimes used to treat severe cases
of rheumatoid arthritis [57]. The remaining candidate
drugs associated with RA and ESR1 directly modulate
estrogen signaling. Tamoxifen and fulvestrant, are select-
ive estrogen receptor modulators (SERMs), that act as
antagonists in breast and agonists in other tissue. Tam-
oxifen has been shown to exert anti-inflammatory effects
in human RA cell cultures [58, 59]. Additionally, other
SERMs currently show promise in treating RA in mouse
models of both genders [60, 61]. However, estrogen
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receptor antagonists have also been reported to induce
RA like symptoms in female subjects [62] (female mice),
[63]. Likewise exemestane, an irreversible steroidal aro-
matase inactivator, has been suggested to induce or re-
veal RA in female subjects [64–66]. The discrepancy in
effects may be attributable to the influence of gender on
tamoxifen-induced biochemical changes [67, 68].
Though based on gene expression in peripheral blood,
these results are nonetheless consistent with the involve-
ment of a neuroinflammatory component in GWI [6]. Es-
trogen plays a significant role in inflammation in general
[54], and neuroinflammation specifically [69], mediating
via astrocytes neuroprotective effects on clinical function,
inflammation in the central nervous system, and axonal
loss [70]. Furthermore, estrogen receptor α moderates the
cytokine- and chemokine-mediated neuroinflammatory
response [71]. SERMs, including tamoxifen and fulves-
trant, appear to have an important anti-inflammatory role
[72] and are thus a promising treatment avenue for GWI.
However, as we have found GWI subjects under maximal
exercise challenge exhibit increased activation of pathways
involving NF-κB [13] the tendency of SERMs to increase
activity of the nuclear NFκB complex [73] must be taken
into consideration. Evidence also suggests a role for estro-
gen and estrogen receptors in Amyotrophic Lateral Scler-
osis (ALS). The incidence and prevalence of ALS are
greater in men than in women [74] and evidence supports
the notion that endogenous female hormones have a neu-
roprotective effect on motor neurons [75, 76]. This is of
import as Gulf War veterans have been shown to develop
amyotrophic lateral sclerosis (ALS) at twice the rate of
non-deployed era veterans [77, 78]. Our analysis is con-
sistent with this showing a GA value of 49 % between ALS
and GWI. Early phase II trials of tamoxifen in ALS have
demonstrated preliminary efficacy [79, 80], and therefore
may be of therapeutic benefit for ALS like symptoms asso-
ciated with GWI. Additionally, estrogen receptor agonists
and estrogen have been shown to attenuate TNF-α in-
duced apoptosis in motor neurons [75, 81]. While SERMs
and TNF-α inhibitors provide novel treatment avenues for
GWI, further analysis must be performed.
Conclusions
Collectively this work supports a treatment strategy that
would target both immune and sex hormone signaling in
GWI. Interestingly this aligns with our recent studies of
altered neuroendocrine-immune homeostasis in GWI
using computational models of known immune, stress
(hypothalamic-pituitary-adrenal) and sex (hypothalamic-
pituitary-gonadal) hormone signaling [82, 83]. In both
these studies we found the cross-talk between immune
and sex steroid signaling could in principle support al-
ternate neuroendocrine-immune regulatory modes that
resemble chronic GWI-associated signatures. Specifically
we found evidence in this analysis that GWI may be asso-
ciated with dysregulation in genetic pathways involved in
immune signaling, particularly TNF-α, signaling, and sex
steroid signaling, as mediated by p38 MAPKs. When com-
pared to a set of human disease conditions GWI most
closely resembles brain disorders with musculoskeletal
problems and dysregulation of immunity, consistent with
previously observed reports. Overall, while specific drugs
have been highlighted the general findings of our study
suggest the use of TNF-α immunosuppressive agents and
SERMs, either individually or in conjunction, in the treat-
ment of GWI. Further analysis of these treatment avenues
will ultimately reveal their efficacy.
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